Autologous Human Adipose-Derived Mesenchymal Stem Cells in Alzheimer's Disease

NCT ID: NCT04855955

Last Updated: 2024-02-07

Basic Information

• Recruitment Status: NO_LONGER_AVAILABLE
• Study Classification: EXPANDED_ACCESS

Brief Summary

This is a single patient emergency expanded access clinical study to assess the safety of administering autologous AdMSCs to an incurable Alzheimer disease patient. The study subject will be evaluated for disease-associated severity according to symptoms, cognitive function, memory, and quality of life.

Conditions

Alzheimer Disease

Interventions

Adipose-Derived Mesenchymal Stem Cells

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• The patient is diagnosed with later stage of Alzheimer Disease with sever cognitive disability.
• All current anti-Alzheimer medicines cannot prevent disease progression and the patient's mental and physical ability persistently declined
• Patient's legal guardian and caregiver must voluntarily sign an approved written consent form after ample explanation of the proposed therapy.

Exclusion Criteria

• Current diagnosis of malignancy
• Renal/liver dysfunction: Exceed two times as normal subject
• Pregnant or nursing
• Received other trial drugs within 30 days after participation of this study
• Experienced major surgery or trauma in the last 14 days

• Accepts Healthy Volunteers: No

Sponsors

Celltex Therapeutics Corporation

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Richard L Neel, M.D.

Role: PRINCIPAL_INVESTIGATOR

Little Alsace Urgent Care Center

Other Identifiers

CTXSP0001

Identifier Type: -

Identifier Source: org_study_id